Affimed NV (AFMDQ)
0.0003
0.00 (0.00%)
USD |
OTCM |
Jan 12, 14:03
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0049M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -99.97% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.0% |
Profile
| Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany. |
| URL | http://www.affimed.com |
| Investor Relations URL | https://www.affimed.com/investors |
| HQ State/Province | Baden Wuerttemberg |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Jun. 09, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany. |
| URL | http://www.affimed.com |
| Investor Relations URL | https://www.affimed.com/investors |
| HQ State/Province | Baden Wuerttemberg |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Jun. 09, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |